Skip to main content
Top
Published in:

11-03-2024 | Osteosarcoma | Case Report

Bizarre parosteal osteocondromatous proliferation (BPOP) of the acromion with soft tissue recurrence

Authors: John Karp, Faizan Malik, Paul J. Zhang, Hamza Alizai

Published in: Skeletal Radiology | Issue 12/2024

Login to get access

Abstract

Bizarre parosteal osteochondromatous proliferation (BPOP) is a benign but rare periosteal-originating chondrogenic tumor. It commonly arises from the hands and feet. It is slow-growing and often presents as a painless lump. On imaging, the mass is well-marginated and almost always remains contiguous with the cortical bone. Histologically, the lesion is composed of a disorganized admixture of fibrous tissue, bone, and cartilage with bizarre features. Treatment is surgical and local recurrence is common contiguous with bone. This case report demonstrates an uncommon acromial BPOP with the first reported recurrence not contiguous with the underlying cortex.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Bizarre parosteal osteocondromatous proliferation (BPOP) of the acromion with soft tissue recurrence
Authors
John Karp
Faizan Malik
Paul J. Zhang
Hamza Alizai
Publication date
11-03-2024
Publisher
Springer Berlin Heidelberg
Published in
Skeletal Radiology / Issue 12/2024
Print ISSN: 0364-2348
Electronic ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-024-04646-y

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest